Held med pipelinen kan gøre Zealand Pharma til opkøbsmål
Tålmodighed har betalt sig for de aktionærer, der har holdt ud i det danske biotekselskab Zealand Pharma, der i de første ti år af sin eksistens på aktiemarkedet i København svingede om udgangspunktet i kurs 86.
I det seneste år er aktiekursen mere end fordoblet, og er steget 170 pct., men ifølge investeringsbanken Carnegie er potentialet slet ikke udtømt, da selskabet kan gå hen og blive et opkøbsmål i de kommende år.
....
https://borsen.dk/nyheder/virksomheder/artikel/1/396647/held_med_pipelinen_kan_goere_zealand_pharma_til_opkoebsmaal.html
Tålmodighed har betalt sig for de aktionærer, der har holdt ud i det danske biotekselskab Zealand Pharma, der i de første ti år af sin eksistens på aktiemarkedet i København svingede om udgangspunktet i kurs 86.
I det seneste år er aktiekursen mere end fordoblet, og er steget 170 pct., men ifølge investeringsbanken Carnegie er potentialet slet ikke udtømt, da selskabet kan gå hen og blive et opkøbsmål i de kommende år.
....
https://borsen.dk/nyheder/virksomheder/artikel/1/396647/held_med_pipelinen_kan_goere_zealand_pharma_til_opkoebsmaal.html
25/2 2020 19:02 exitnu 0
82045 "En interesseret køber skal ifølge Carnegie slippe mere end 20 mia. kr. for at få fat på Zealand Pharma"
Ikke så ringe endda
Ikke så ringe endda
26/2 2020 02:30 tommycarstensen 282066 2008-09-02
Goldman Sachs starter dækning af NeuroSearch med Køb
https://npinvestor.dk/nyheder/goldman-sachs-starter-d%C3%A6kning-af-neurosearch-med-k%C3%B8b
"I vores øjne afspejler aktierne ikke fuldt ud profilen på et selskab, som kan have fire midler i *fase 3* i 2009, eller som kan være et potentielt *opkøbsmål*, skriver Goldman Sachs."
2019-07-24
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally
2018-01-30
Biotech Zealand Pharma bets on self-marketing over big pharma partnerships
https://www.reuters.com/article/zealand-strategy/biotech-zealand-pharma-bets-on-self-marketing-over-big-pharma-partnerships-idUSL8N1PK518
"Sales of Soliqua, which is a combination of insulin and a GLP-1, has been *below both analysts and Sanofi's own expectations* since the drug was launched in the United States a year ago, Sanofi said in its third-quarter results in November."
2019-05-17
U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
https://www.takeda.com/en-us/newsroom/news-releases/2019/u.s.-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs/
Gattex-salg 2019Q3YTD 46.9 JPYmia = 430 USDmio.
*Hvis* Zealand lykkes (godkendelsen *og* salg) med glepaglutid, saa kan selskabet sagtens vaere 20 milliarder kroner vaerd. Dasiglucagon tror jeg fortsat ikke paa. Dertil er baade alternativerne og nye laegemidler, der ikke forarsaager hypoglykaemi for gode.
Goldman Sachs starter dækning af NeuroSearch med Køb
https://npinvestor.dk/nyheder/goldman-sachs-starter-d%C3%A6kning-af-neurosearch-med-k%C3%B8b
"I vores øjne afspejler aktierne ikke fuldt ud profilen på et selskab, som kan have fire midler i *fase 3* i 2009, eller som kan være et potentielt *opkøbsmål*, skriver Goldman Sachs."
2019-07-24
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
https://investor.lilly.com/news-releases/news-release-details/baqsimitm-glucagon-nasal-powder-3-mg-first-and-only-nasally
2018-01-30
Biotech Zealand Pharma bets on self-marketing over big pharma partnerships
https://www.reuters.com/article/zealand-strategy/biotech-zealand-pharma-bets-on-self-marketing-over-big-pharma-partnerships-idUSL8N1PK518
"Sales of Soliqua, which is a combination of insulin and a GLP-1, has been *below both analysts and Sanofi's own expectations* since the drug was launched in the United States a year ago, Sanofi said in its third-quarter results in November."
2019-05-17
U.S. FDA Approves GATTEX® (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)
https://www.takeda.com/en-us/newsroom/news-releases/2019/u.s.-fda-approves-gattex-teduglutide-for-children-1-year-of-age-and-older-with-short-bowel-syndrome-sbs/
Gattex-salg 2019Q3YTD 46.9 JPYmia = 430 USDmio.
*Hvis* Zealand lykkes (godkendelsen *og* salg) med glepaglutid, saa kan selskabet sagtens vaere 20 milliarder kroner vaerd. Dasiglucagon tror jeg fortsat ikke paa. Dertil er baade alternativerne og nye laegemidler, der ikke forarsaager hypoglykaemi for gode.
26/2 2020 02:34 tommycarstensen 182067 Jeg har ikke set de seneste profetier. Her fra februar 2018:
Global Short Bowel Syndrome Market, 2017 to 2025: Growing Prescriptions of Gattex and Revestive in U.S. and Europe Respectively is Boosting the Growth of the Market
https://www.globenewswire.com/news-release/2018/02/07/1335146/0/en/Global-Short-Bowel-Syndrome-Market-2017-to-2025-Growing-Prescriptions-of-Gattex-and-Revestive-in-U-S-and-Europe-Respectively-is-Boosting-the-Growth-of-the-Market.html
"The market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025."
Global Short Bowel Syndrome Market, 2017 to 2025: Growing Prescriptions of Gattex and Revestive in U.S. and Europe Respectively is Boosting the Growth of the Market
https://www.globenewswire.com/news-release/2018/02/07/1335146/0/en/Global-Short-Bowel-Syndrome-Market-2017-to-2025-Growing-Prescriptions-of-Gattex-and-Revestive-in-U-S-and-Europe-Respectively-is-Boosting-the-Growth-of-the-Market.html
"The market was valued at US$ 315.1 Mn in 2016, and is expected to reach US$ 2,901.0 Mn by 2025, expanding at a CAGR of 27.5% from 2017 to 2025."
